Intravenous Administration of REOLYSIN® for Patients with Relapsed Multiple Myeloma
In May 2011, Oncolytics announced that the US National Cancer Institute (NCI) intended to conduct a Phase I study of REOLYSIN® alone in patients with relapsed multiple myeloma. The NCI is sponsoring the trial under its Clinical Trials Agreement with Oncolytics, while Oncolytics will provide clinical supplies of REOLYSIN®.
The primary endpoint for the dose escalation portion of this study will be adverse events using CTCAE criteria. Correlative studies will focus on the efficiency with which reovirus replicates in patient myeloma cells. Investigators will use standard cohorts-of-three Phase I dose escalation design with three to six patients being treated at each dose level. Secondary endpoints will include clinical benefit, duration of response and time to progression.
- May 10, 2011: Oncolytics Biotech Inc. Announces Phase I Multiple Myeloma Cancer Study (Press Release)